AstraZeneca (LSE: AZN) and Daiichi Sankyo’s (TYO: 4568) Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.
This approval broadens the indication for the HER2-directed antibody drug conjugate across Europe to earlier use in HER2-positive metastatic breast cancer.
"Potential for this medicine to set a new benchmark in the treatment of HER2-positive metastatic breast cancer"The submission was based on the DESTINY-Breast03 results in which Enhertu demonstrated a 72% reduction in the risk of disease progression or death versus trastuzumab emtansine, a drug developed under the brand name Kadcyla by the Roche (ROG: SIX) subsidiary Genentech.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze